Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 599 is a member of the zinc finger protein family, characterized by the presence of zinc finger domains that facilitate DNA binding[3][6]. It is predicted to act as a DNA-binding transcription factor specific to RNA polymerase II, with a regulatory role in gene expression and transcriptional control[3][6]. The protein is localized in the nucleus and may participate in the modulation of other genes' transcriptional activity. ZNF599 is classified as a protein-coding gene and has been associated with clinical disorders such as chromosome 19q13.11 deletion syndrome and developmental and epileptic encephalopathy 52[3]. There is no current evidence indicating it is a primary therapeutic target or that any approved drugs directly interact with it[3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 599 (ZNF599).